Press Releases GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 06:05:08 2025-07-14 EDT			5-day change	1st Jan Change
1,411.50 ^GBX	+0.21%		+1.12%	+4.80%

05:55am	GSK Seeks FDA Approval to Expand RSV Vaccine Use to At-Risk Adults Aged 18-49	MT
04:43am	GSK: seeks FDA approval to expand Arexvy indication	CF

Press Releases

GSK : US FDA accepts application to review expanded use of GSK’s RSV vaccine, Arexvy, for adults 18-49 at increased risk	02:09am	PU
GSK begins shipping influenza vaccine doses for the 2025-26 flu season	07-10	BU
GSK : Q2 2025 pre announcement aide memoire	07-09	PU
GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease	07-08	AQ
GSK : ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025	07-08	PU
GSK : Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5	06-25	PU
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis	06-24	BU
GSK : Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary biliary cholangitis (PBC)	06-23	PU
GSK : Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease.	06-20	PU
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US	06-16	BU
GSK : RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older	06-13	PU
GSK Plc - Director/PDMR Shareholding	06-12	PR
GSK : licenses Shigella vaccine candidate to Bharat Biotech for continued development	06-12	PU
GSK : data at ASCO and EHA showcase latest research and innovation across the oncology portfolio	05-29	PU
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee	05-28	AQ
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)	05-22	BU
GSK : Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)	05-22	PU
GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis	05-09	BU
GSK : GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)	05-08	PU
GSK : continues to advance the future of respiratory medicine and patient care with new data at ATS	05-02	PU
GSK : Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine	04-30	PU
Glaxo: Q1 Earnings Snapshot	04-30	AQ
GSK : makes strong start to 2025 with growth in sales, profits and earnings	04-30	PU
GSK : Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma	04-17	PU
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices	04-16	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : Despite its challenges, GSK remains investable

May 21, 2025 at 10:08 am

GSK CEO on US Expansion, M&A, Drug Pipeline, Trump

January 13, 2025 at 03:03 pm

GSK plc : Back on track

May 03, 2024 at 05:17 am